We spend billions on modern cancer therapies, build impressive hospital wards, and purchase the most expensive diagnostic equipment. Yet, in survival statistics for many dangerous diseases, we remain stagnant. Why? Because modern medicine has fallen into a trap of its own success – it has become a master at saving lives on the brink of disaster but has completely forgotten how to build a barrier at the top.
Imagine a system that's excellent at extinguishing fires, equipped with gleaming fire trucks and highly trained firefighters, but... systematically refuses to install smoke detectors in homes. This, in a simplified sense, is how healthcare operates today in Poland and many European countries.
The current model is inherently reactive – focused solely on intervention. It only kicks in when the fire is already raging: when sharp pain appears, a palpable lump is found, or an acute heart attack occurs. For individuals whose diseases develop asymptomatically, the system practically doesn't exist. These people disappear from medicine's radar, only to reappear suddenly, often in an advanced stage.
Demographic statistics from the Central Statistical Office (GUS) are relentless: cardiovascular diseases account for approximately 37% of deaths in Poland, and cancer for another 25%. Together, this is over 60% of our mortality causes. The greatest tragedy of these numbers is that a vast portion of these premature deaths could be prevented if the risk were identified at the "smoldering ember" stage, not the "rooftop inferno."
The Paradox of 10.7 Percent and the System's Blind Spot
From a logical standpoint, if we pump more money into a sector, we should expect measurably better results. However, in medicine, this mechanism has become firmly stuck, exposing the flaws of a commercial, reactive approach to health.
Polish oncology is a prime example. According to European reports (including the European Cancer Inequalities Registry - ECIR), Poland has seen the highest increase in oncology care expenditures among European Union countries in recent years – a staggering 10.7%. What was the societal impact? Unfortunately, we haven't observed a proportional decrease in mortality. While our overall incidence of oncological diseases is within the EU average, our mortality rate significantly exceeds it.
Furthermore, the European Cancer Screening Policy Index report mercilessly shows that Poland (with a score of 69.4%) still lags far behind leaders like Slovenia (91.2%) or Scandinavian countries when it comes to the effectiveness of early detection programs.
Where does the problem lie? In systemic delays, which manifest in two deadly stages:
The bottleneck of secondary prevention: A patient with an asymptomatic disease doesn't seek medical attention because they simply don't feel sick, and the system doesn't facilitate prevention in their daily lives.
Intra-systemic delays: Once symptoms appear, the fragmentation of facilities, lack of coordination, and months-long queues mean that proper treatment begins far too late. We give the disease valuable time to progress, and then we spend millions on heroic battles.
Time for "Leapfrog," a Medical Technological Jump
The solution to this stalemate isn't to pour more billions into an outdated model of treatment confined within hospital walls. We need a transformation that, in the technology world, is called "leapfrog" (technological jump). This concept means directly implementing the most advanced and effective solutions, completely bypassing outdated intermediate stages. We are familiar with this phenomenon from other industries:
Africa skipped the copper cable era: Instead of decades spent building costly landline and traditional banking infrastructure, the continent immediately jumped to mobile telephony and mobile payments.
Poland skipped the paper check era: While the West evolved its check system over decades, the Polish banking sector immediately adopted mass electronic banking, contactless cards, and the innovative BLIK system.
Healthcare must make precisely the same leap today. Instead of building ever-larger waiting rooms in crowded clinics, we need to create an architecture of prevention within the patient's daily life. Health is a fundamental human right, so modern tools must move out of clinic walls and directly into our homes.
Proof of Effectiveness: A Lesson from Szczecin
If anyone thinks proactive medicine is just a futuristic theory, they only need to look at the last 30 years of work by the genetic oncology team at Pomeranian Medical University (PUM) under the leadership of Prof. Jan Lubiński. They have demonstrated, not only in Poland but worldwide, the significance of cancer prevention when done properly. Their story is a perfect example of how staying ahead of the curve and effectively outmaneuvering disease works in practice.
Mutations in the BRCA1 and BRCA2 genes are inherited defects in our biological shield that drastically increase the risk of breast and ovarian cancer. A pioneer in research on these predispositions in Poland is Prof. Jan Lubiński's team from Szczecin. Since the early 1990s, they have created one of the world's largest registries of high-risk families, proving that genetic destiny can be effectively changed. The team developed a comprehensive model integrating genetics, family history, and environmental monitoring (including blood element concentration analysis), and demonstrated its ability to save lives on a massive scale, so much so that scientists from around the world still travel to Szczecin to learn from these discoveries. Furthermore, testing nearly 500,000 individuals has allowed Polish scientists to discover that, in addition to gene mutations (like BRCA1 or BRCA2), maintaining optimal selenium (around 100 µg/l) and zinc (around 1100 µg/l) levels in the blood, while avoiding toxic arsenic, is critical for cancer risk and patient survival.
The result? Women in Poland enrolled in this integrated proactive care program for high-risk families have tumors detected at an average size of only 21.1 mm (compared to about 28.6 mm in the USA). Thanks to such early detection, the 10-year survival rate is nearly 78%, surpassing data from many developed Western countries. This is hard clinical evidence that data-driven prevention truly works.
Three Pillars of Prevention Architecture
How can these outstanding scientific achievements be translated into a system accessible to everyone, regardless of financial status? The focal point shifts from the sick patient to the seemingly healthy individual, supported in their daily environment by three key pillars:
1. Digital Health Pedigree (Genogram) Instead of Passivity
The system cannot wait. It must proactively reach us using intelligent algorithms. The foundation here is the digital genogram – a detailed, structured interview about family medical history. Today, up to 60-70% of patients do not undergo a full family history analysis with their doctor due to lack of time (average visit lasts only 12 minutes). Intelligent applications can do this asynchronously (at any time, without rush), automatically assigning us to the appropriate cardiovascular or oncological risk group and suggesting tests before any symptom appears.
2. End of Data Silos – Technology as a Coordinator
We are moving from an era of fragmented data (where each clinic and laboratory is a separate, closed silo) to full integration. Laboratory test results (e.g., elemental profiling from Szczecin), information from genetic counseling centers, and central public platforms (like the Internet Patient Account) must communicate securely. Technology becomes the invisible coordinator, analyzing these connections 24 hours a day, ensuring no risk goes unnoticed.
3. Doctor-in-the-Loop
Fears that modern technologies or algorithms will replace doctors are unfounded. The technological leap actually enhances the specialist's role. Instead of wasting time on routine prescription writing, tedious history taking, or sifting through scattered result sheets, automation takes care of these tasks for medical professionals. When the system detects an emerging anomaly, the patient arrives at the doctor's office as a "prepared case." The doctor receives a synthesized, multidimensional risk profile and gains what is most valuable: time for a deep, empathetic conversation and an accurate therapeutic decision.
Tools That Are Already Changing the Game
Implementing the medical "leapfrog" doesn't require waiting for legislative revolution. The tools to achieve this mission are already within reach. An example of such an integrated ecosystem is the Wellysa app, which acts as a mobile health and prevention center. Application relieves patients of the burden of getting lost in the system: it allows for easy creation of a health profile and then develops a personalized prevention plan tailored to your biological needs and family history. Moreover, from your phone, it enables direct ordering of key diagnostic and genetic tests and quick consultation with a specialist. This is technology that doesn't create financial barriers but offers equal opportunities for effective defense.
For prevention to work, the language must also change. Medicine must abandon jargon for clear communication. Results and recommendations on our phones must be simple and visual (e.g., risk categorization using clear colors), suggesting concrete, easy-to-implement actions. Only then will we be motivated to take care of ourselves before we feel unwell.
The real problem of modern healthcare is not a lack of machines or academic knowledge. We have technologies with scientifically proven effectiveness. The challenge is to start using them in a coherent, proactive, and widespread manner. Medical leapfrog is a change in thinking – prioritizing prevention architecture over a culture of firefighting. It's high time to extend health far beyond the narrow confines of clinics.
